Silver Book Fact

A prostate cancer vaccine, sipleucel-T immunotherapy, in men with metastatic castration-resistant prostate
cancer, reduced the risk of death by 22 percent compared to placebo, and represented a 4.2 month improvement in median survival.

Kantoff, P, C Higano, N Shore, E Berger, E Small, D Penson, et al. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. NEJM. 2010; 363: 411-22. http://www.nejm.org/doi/full/10.1056/NEJMoa1001294

Reference

Title
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Publication
NEJM
Publication Date
2010
Authors
Kantoff, P, C Higano, N Shore, E Berger, E Small, D Penson, et al.
Pages
411-22
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • FDA Cancer Approvals for Aug 2014 to July 2015
     
  • Medicines in Devlopment for Cancer, 2008  
  • New Drug Increases Brain Cancer Survival Rate: Temozolomide is the first new drug in over 30 years to treat glioblastoma, a severe form of brain cancer  
  • Following the current path, breast cancer incidence rate will increase by 50.8% between 2003 and 2023. If an alternative path is taken, cases will increase by 32.2% between 2003 and…  
  • Because of advances in treatment, the 5-year survival rate for people with actue lymphocytic leukemia has increased from 38% in 1974-1976 to 65% in 1995-2001.